**CURRICULUM VITAE**

Name: Louis Michael Staudt

Date and Place of Birth: May 11, 1955, Detroit, Michigan

Work Address: Metabolism Branch, National Cancer Institute, Bldg. 10,
Rm. 4N114,

NIH, 9000 Rockville Pike, Bethesda, MD 20892

Education: M.D. University of Pennsylvania School of Medicine, 1982

Ph.D., Immunology (Laboratory of Walter Gerhard)

University of Pennsylvania School of Medicine, 1982

B.A., Harvard College, Biochemistry, Cum Laude, 1976

[Work Experience:]{.underline}

June 1982 - June 1983 Postdoctoral Fellow, Wistar Institute

Philadelphia, PA (Laboratory of Walter Gerhard)

June 1983 - June 1984 Intern, Internal Medicine, Presbyterian - Univ. of
PA

Medical Center, Philadelphia, Pennsylvania

July 1984 - Jan. 1988 Postdoctoral Fellow, Whitehead Institute for
Biomedical Research

Cambridge, Mass. (Laboratory of David Baltimore)

Feb. 1988 - May 1995 Senior Staff Fellow, Metabolism Branch, National
Cancer Institute,

NIH, Bethesda, Maryland

May 1995 - Dec. 2001 Senior Investigator, Metabolism Branch, National
Cancer Institute,

NIH, Bethesda, Maryland

Dec. 2001 - present Chief, Lymphoid Malignancies Section, Metabolism
Branch,

National Cancer Institute, NIH, Bethesda, Maryland\
2003 - present Adjunct Professor of Pathology and Laboratory Medicine,
University of\
Pennsylvania School of Medicine, Philadelphia, PA

Aug 2003 -- Feb. 2008 Senior Biomedical Research Service, National
Institutes of Health

Oct 2004 - present Deputy Chief, Metabolism Branch, National Cancer
Institute,

NIH, Bethesda, Maryland

[Awards and Honors:]{.underline}

1982 Stuart Mudd Award in Microbiology, Univ. of Pennsylvania

1982 Baldwin Lucke Memorial Prize in Experimental Medicine and Biology,
Univ. of Pennsylvania

1976-1982 Medical Scientist Training Program Award, Univ. of
Pennsylvania

1984-1987 Fellowship, Jane Coffin Child Memorial Foundation for Cancer
Research

1988-1992 Investigator Award, Cancer Research Institute

1989 Trainee Award, American Federation for Clinical Research

1992 Arthur S. Fleming Award

1998 NIH Director\'s Award-Cancer Genome Anatomy Project

2000 NIH Director\'s Award-Microarray Tech Group\
2000 Robert Sternlicht Lecture in Pharmacology and Cancer Biology,\
Case Western Reserve University School of Medicine\
2001 Blass Lecture in Genetics, Univ. of Arkansas Medical School\
2001 Mary Chupp Lecturer in Hematology/Oncology, New England Medical
Center\
2002 Kenneth B. McCredie Memorial Lecture, Leukemia and Lymphoma
Society\
2002 NIH Merit Award\
2003 Julia Hudson Freund Memorial Lecture, Washington Univ. School of
Medicine

2003 Peacock Memorial Lecturer in Pathology, U. of Texas Southwestern
Medical Center

2003 2003 Guest Lecturer, Leukemia Research Fund, UK

2004 Elected to Association of American Physicians

2006 NIH Director's Award

[Medical License:]{.underline} Maryland

[Committees]{.underline}

1997-1999 Cancer Genome Anatomy Project Steering Committee, NCI

1997-present Microarray Steering committee, NCI

1997-1999 Co-chair, 1999 FASEB Summer Research Conference on
Hematological

Malignancies

1999-present Co-chair, Lymphoma/Leukemia Molecular Profiling Project,
NCI

1999-2002 Steering Committee, HHMI/NIH Research Scholars Program

2000-2001 Scientific Advisory Board, Biomedical Genomics Center, Univ.
of Minnesota

2000 2001 Steering Committee, NCI, Program Review Group, Lymphoma,
Leukemia,

Myeloma

2000-present Editorial Board, Genome Biology

2001-present Editorial Board, Cancer Cell

2001-2003 Co-organizer, 2003 Keystone Symposium on B Cells & Antibodies:
Laboratory to Clinic

2001-present Steering Committee, Faculty of Genetics, Genomics and
Proteomics, NCI

2002-2005 Consulting Editor, Journal of Clinical Investigation

2002-present Editorial Board, Immunological Reviews\
2002-2003 Reviewer, Specialized Center of Research Program, Leukemia and
Lymphoma Society

2002-present Scientific Advisory Board, International Conference on
Malignant Lymphoma, Lugano, Switzerland

2002-2007 External Advisory Board, Dana Farber/Harvard Cancer Center

2004-present Association of American Physicians

2004-present Scientific Advisory Board, Multiple Myeloma Research
Foundation

2005-2006 Education Committee for the 97th American Association for
Cancer Research Annual Meeting

2006-present Scientific Advisory Board, Lymphoma Research Foundation

2008-present Lymphoma Research Foundation Follicular Lymphoma Consortium
Executive Committee

2008-present Co-Chairman, Program Committee, 2009 American Association
for Cancer Research

> Annual Meeting

[Recent Invited Lectures]{.underline}

Jan 2002 Yale University Medical School, Dept. of Genetics, New Haven,
CT

Jan 2002 Keystone Symposium, "T Lymphocyte Activation, Differentiation
and Death, Keystone, CO

Jan 2002 Dana Farber Cancer Center, Seminars in Oncology, Boston, MA

Jan 2002 Cooperband Lecture, Boston Univ. School of Medicine, Boston, MA

Feb 2002 Keystone Symposium, "NF-kappaB: Bench to Bedside", Keystone, CO

Mar 2002 New York University School of Medicine, New York, NY

Mar 2002 University of Freiburg, Dept. of Molecular Immunology,
Freiburg, Germany

Mar 2002 Advance in Plasma Cell Formation and Tumorigenesis Roundtable,
New York, NY

Mar 2002 UCLA School of Medicine Cancer Center, Los Angeles, CA

Mar 2002 IX International Workshop on CLL, San Diego, CA

Mar 2002 Joslin clinic, Boston, MA

Apr 2002 Molecular Mechanisms of Pathogenesis, Wuerzburg, Germany

Apr 2002 University of Virginia Cancer Center, Charlottesville, VA

Apr 2002 University of Chicago, Program in Immunology, Chicago, IL

May 2002 Van Andel Research Institute, Grand Rapids, MI

May 2002 Harvard Medical School, Immunology Lecture Series, Boston, MA

May 2002 European Society of Hematopathology, Siena, Italy

June 2002 8^th^ International Conference on Malignant Lymphoma, Lugano,
Switzerland.

June 2002 2002 Rockefeller Symposium, "Cancer Research: From Bench to
Bedside", New York, NY

July 2002 Federated Of Clinical Immunology Societies Annual Meeting, San
Francisco, CA

July 2002 Millenium Pharmaceuticals, Boston, MA

Sept 2002 FEBS International Summer School on Immunology, Ionian
Village, Greece

Sept 2002 After Sequencing the Human Genome: New Approaches to Tumor
Research, Diagnosis and Therapy,

Bonn, Germany

Oct 2002 Cancer Intervention 2002, Van Andel Institute, Grand Rapids, MI

Nov 2002 Kenneth B. McCredie Memorial Lecture, Lymphoma and Leukemia
Society Meeting, St. Louis, MO

Nov 2002 ASCO Molecular Therapeutics Symposium, San Diego, CA

Nov 2002 Keynote Speaker, University Health Network Research Day,
Toronto, Ontario, Canada

Nov 2002 Keynote Speaker, EORTC-NCI-AACR Symposium on Molecular Targets
and Cancer Therapeutics,

Frankfurt, Germany

Nov 2002 Roche symposium on hematological cancers, Paris, France

Dec 2002 American Society of Hematology annual meeting, Philadelphia, PA

Jan 2003 Keystone Symposium on B Cells & Antibodies: Laboratory to
Clinic, Keystone, CO

Feb 2003 Miami Nature Biotechnology Winter Symposium, Miami, FL

Feb 2003 IBC/NCI symposium \"Genomics & Proteomics Technological
Advances in Cancer Research, Bethesda, MD

Feb 2003 UCLA/Southern California Lymphoma Group, Los Angeles, CA

Mar 2003 Julia Hudson Freund Memorial Lecture, Washington Univ. School
of Medicine, St. Louis, MO

Mar 2003 Netherlands Cancer Institute, Amsterdam, Netherlands

Mar 2003 Danish Society of Hematology, Denmark

Mar 2003 Lymphoma Workshop, North Berwick, Scotland

Apr 2003 Taking Cancer Genomics to the Clinic, Banbury conference, Cold
Spring Harbor, NY

Apr 2003 Stephen Robinson Visiting Professor, Beth Israel Deaconess
Medical Center, Boston, MA

May 2003 Peacock Memorial Lecturer in Pathology, Univ. of Texas
Southwestern Medical Center, Dallas, TX

June 2003 German Society of Pathology Annual Meeting, Bamburg, Germany

June 2003 FASEB conference: Lymphocytes and the Immune System:
Molecular, Cellular & Integrative, Tucson, AZ

July 2003 Targeted Therapies for the Treatment of Hematological
Malignancies, Kona, Hawaii.

July 2003 FASEB conference: Hematological Malignancies, Saxton's River,
VT

Aug 2003 Salk/EMBL -- Oncogenes and Growth Control 2003, San Diego, CA

Sept 2003 Univ. of Pennsylvania, Hematology/Oncology Lecture Series,
Philadelphia, PA

Oct 2003 International Workshop on Non-Hodgkin Lymphoma,
Niagara-on-the-Lake, Ontario, Canada

Oct 2003 International Workshop on Chronic Lymphocytic Leukemia, Stresa,
Italy

Nov 2003 Annual Guest Lecture, Leukaemia Research Fund, London, UK

Nov 2003 Sanger Center, Cambridge, UK

Dec 2003 American Society of Hematology annual meeting, San Diego, CA

Jan 2004 Keystone symposium, NF-kappaB: Biology and Pathology, Snowbird,
UT

Jan 2004 6^th^ Joint Conference of the American Association for Cancer
Research and the Japanese Cancer

Association, Waikoloa, HI

Feb 2004 The Molecular Taxonomy of Cancer; The 2004 CNIO Symposium,
Madrid, Spain.

Mar 2004 American Association for Cancer Research Annual Meeting,
Orlando, FL

Apr 2004 Univ. of Pennsylvania Dept. of Pathology and Laboratory
Medicine, Philadelphia, PA

Apr 2004 Memorial Sloan Kettering Cancer Center, New York, NY

Apr 2004 American Society of Investigative Pathology Annual Meeting,
Washington, DC

May 2004 Affymetrix Partners Conference, VA

July 2004 International Immunology Congress, Montreal, Canada

Sept 2004 Baylor College of Medicine, Grand Rounds, Houston, TX

Oct 2004 The REAL classification:20 years later, Bologna, Italy

Feb 2005 AACR Oncogenomics meeting, San Diego, CA

Feb 2005 Lymphoma Focus Workshop, Leukemia and Lymphoma Society,
Washington, DC

Mar 2005 Harvard Cancer Center Grand Rounds, Boston, MA

Mar 2005 Keystone conference on B cell development, function, and
disease, Steamboat Springs, CO

Apr 2005 AACR Annual Meeting, Anaheim, CA

May 2005 Childhood Cancer Targeted Therapeutics Workshop, Arlington, VA.

June 2005 9^th^ International Conference on Malignant Lymphoma, Lugano,
Switzerland.

July 2005 Pan-Pacific Lymphoma Conference, Kauii, HI

July 2005 M.D.-Ph.D. National Conference, Keystone, CO

Aug 2005 FASEB conference on Hematological Malignancies, Saxtons River,
VT

Aug 2005 Think Tank on Molecular Targets in Lymphoid Malignancies,
Bethesda, MD

Sept 2005 International Workshop on Non-Hodgkin Lymphoma, Miami, FL

Oct 2005 Lupus Research Institute Annual Meeting, New York, NY

Oct 2005 Workshop on Microarrays in Hematological Malignancies, Cascais,
Portugal

Oct 2005 Stem cells and cancer, Titisee,Germany

Dec 2005 American Society of Hematology annual meeting, Atlanta, GA

Mar 2006 NYU School of Medicine, New York, NY

Mar 2006 Keystone conference on NF-kappaB: 20 Years on the Road from
Biochemistry to Pathology

Banff Springs, Alberta, Canada

Apr 2006 American Association for Cancer Research Annual Meeting,
Washington, DC

Apr 2006 Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School
of Medicine, Baltimore, MD

May 2006 Dartmouth University School of Medicine, Hanover, NH

May 2006 Second International Symposium on Childhood, Adolescent and
Young Adult Non-Hodgkin\'s

Lymphoma. New York, NY

June 2006 Annual Meeting, European Hematology Association, Amsterdam,
The Netherlands

July 2006 Gordon conference on Cancer Models and Mechanisms. Smithfield,
RI

Sept 2006 Winning the War Against Cancer: From genomics to bedside and
back. Van Andel Research

Institute, Grand Rapids, MI

Sept 2006 3^rd^ International Conference on Gene Regulation in
Lymphocyte Development, Corfu, Greece

Sept 2006 3^rd^ International Conference on Innovative Therapies for
Lymphoid Malignancies, Palermo, Sicily

Nov 2006 B cells: Bridging basic biology and arthritis, lymphoma and
lupus. Univ. of Pittsburgh Medical

Center, Pittsburgh, PA.

Nov 2006 Personalized Medicine: A world of opportunities. Harvard
Medical School, Boston, MA

Jan 2007 Keystone conference on Immunological Interventions in Human
Disease. Big Sky, MT

Jan 2007 AACR Oncogenomics meeting. Phoenix, AZ

Feb 2007 Keystone conference on B cell development, function, and
disease. Banff Springs, Alberta, Canada

Feb 2007 CNIO conference on lymphoid neoplasms. Madrid, Spain

March 2007 Multiple Myeloma Research Foundation scientific roundtable.
New York, NY

March 2007 ASH-AACR Think Tank on Hematologic Malignancies, Washington,
DC

March 2007 Lymphoma Research Foundation workshop on mantle cell
lymphoma, Chicago, IL

March 2007 MD Anderson, Houston, TX

April 2007 AACR Annual Meeting, Chairman, Major Symposium on Functional
Genomics to Identify Cancer

Targets, Los Angeles, CA

May 2007 Immunology Graduate Student Seminar Series, Columbia Medical
School, New York, NY

July 2007 FASEB conference on Hematological Malignancies, Saxtons River,
VT

Sept 2007 Aggressive Lymphomas, Gottingen, Germany

Sept 2007 ASCO 2007 Novel Therapeutics Development in Lymphoma Workshop,
Aspen, CO

Oct 2007 Lymphoma Research Foundation Indolent Lymphoma Workshop,
Arlington, VA

Oct 2007 AACR Molecular Targets and Cancer Therapeutics, San Francisco,
CA

Nov 2007 Walter Gerhard Symposium, Wistar Institute, Philadelphia, PA

Dec 2007 American Society of Hematology Annual Meeting, Atlanta, GA

Feb 2008 Keystone conference on NF-kB, Banff Springs, Alberta, Canada

March 2008 Symposium in honor of David Baltimore's 70^th^ birthday,
California Institute of Technology,

Pasadena, CA

March 2008 Dept. of Pathology, UCLA, Los Angeles, CA

March 2008 Lymphoma Research Foundation workshop on mantle cell
lymphoma, Dallas, TX

April 2008 AACR Annual Meeting, San Diego, CA

May 2008 University of Michigan, Department of Pathology, Ann Arbor, MI

May 2008 32nd Annual UNC Lineberger Cancer Center Symposium "Cancer Drug
Discovery and

> Development", Chapel Hill, NC

May 2008 Keynote speaker, ESF-EMBO Conference B Cells 2008, St Feliu de
Guixols, Spain

May 2008 University of Barcelona, Department of Pathology, Barcelona,
Spain

June 2008 10th International Conference on Malignant Lymphoma, Lugano,
Switzerland.

BIBLIOGRAPHY

Louis M. Staudt

1\. Gerhard W, Yewdell J, Frankel ME, Lopes AD, Staudt L. Monoclonal
antibodies against influenza virus. In: Kennett RH, McKearn TJ, Bechtol
KB, eds. Monoclonal Antibodies. New York: Plenum 1980;137.

2\. Staudt L, Frankel ME, Yewdell J, Gerhard W. Genetic variation in
viruses analyzed with monoclonal antibodies. In: Bachman PA eds.
Biological Products for Viral Diseases. London: Taylor and Francis
1980;147.

3\. Staudt, LM. The idiotypic and paratypic relations of anti-influenza
virus hemagglutinin antibodies produced by BALB/c mice. In: Berek C,
Etlinger H, Gerhard W, eds. Idiotypes: Antigens on the inside. Basel:
Roche 1981;49.

4\. Staudt LM, Gerhard W, McKean DJ, Bell M, Luedtke R, Weigert M.
Somatic mutation generates significant antibody diversity in the immune
response of BALB/c mice to influenza virus hemagglutinin. In:
Proceedings of New Perspectives in Virology. Rome: 1983;1102.

5\. Staudt LM, Gerhard W. The generation of antibody diversity in the
immune response of BALB/c mice to influenza virus hemagglutinin. I:
Significant variation in repertoire expression between individual mice.
J Exp Med 1983;157:687.

6\. McKean D, Huppi K, Bell M, Staudt L, Gerhard W, Weigert M.
Generation of antibody diversity in the immune response of BALB/c mice
to influenza virus hemagglutinin. Proc Natl Acad Sci 1984;81:3180.

7\. Huppi K, Julius M, Staudt L, Gerhard W, Weigert M. The idiotypes of
Vk21 light chains. Paris: Les Annales d-Immunologie 1984;135c:181.

8\. Clarke SH, Huppi K, Ruezinsky D, Staudt L, Gerhard W, Weigert M.
Inter- and Intraclonal diversity in the antibody response to influenza
virus hemagglutinin. J Exp Med 1985;161:687.

9\. Caton AJ, Brownlee GG, Staudt LM, Gerhard W. Germ-line and somatic
diversity in the antibody response to the influenza virus hemagglutinin.
In: Current Communications in Molecular Biology. NY: Cold Spring Harbor
Laboratory 1985;35.

10\. Clark SH, Huppi K, Ruezinsky D, Staudt LM, Gerhard W, Weigert M.
Antibody diversity in the immune response to influenza virus
hemagglutinin. In: Current Communications in Molecular Biology. NY: Cold
Spring Harbor Laboratory 1985;39.

11\. Caton AJ, Brownlee GG, Staudt LM, Gerhard W. Structural and
functional implications of a restricted antibody response to a defined
antigenic region on the influenza virus hemagglutinin. EMBO J
1985;5:1577.

12\. Staudt LM, Singh H, Sen R, Wirth T, Sharp PA, Baltimore D. A
lymphoid-specific protein binding to the octamer motif of immunoglobulin
genes. Nature 1986;323:640.

13\. Wirth T, Staudt LM, Baltimore D. An octamer oligonucleotide
upstream of a TATA motif is sufficient for lymphoid-specific promoter
activity. Nature 1987;329:174.

14\. Staudt LM, Clerc RG, Singh H, Lebowitz JH, Sharp PA, Baltimore D.
Cloning of a lymphoid-specific cDNA encoding a protein binding the
regulatory octamer DNA motif. Science 1988;241:577.

15\. Ko HS, Fast P, McBride W, Staudt LM. A human protein specific for
the immunoglobulin octamer DNA motif contains a functional homeobox
domain. Cell 1988;55:135-44.

16\. LeBowitz JH, Kobayashi T, Staudt L, Baltimore D, Sharp PA.
Octamer-binding proteins from B or HeLa cells stimulate transcription of
the immunoglobulin heavy-chain promoter in vitro. Genes & Development
1988;2:1227-37.

17\. Lenardo MJ, Staudt L, Robbins P, Kuang A, Mulligan R, Baltimore D.
Repression of the immunoglobulin heavy chain enhancer in mouse
teratocarcinoma cells is associated with the presence of a novel octamer
binding factor. Science 1989;243:544-6.

18\. Takimoto M, Quinn JP, Farina AR, Staudt LM, Levens D. fos/jun and
octamer-binding protein interact with a common site in a negative
element of the human c-myc gene. J Biol Chem 1989;264:8992-9.

19\. Petryniak B, Staudt LM, Postema C, McCormick WT, Thompson CB.
Characterization of chicken octamer-binding proteins demonstrates that
POU-containing homeotic transcription factors have been highly conserved
during vertebrate evolution. Proc Natl Acad Sci 1990;87:1099-103.

20\. Clark SH, Staudt LM, Kavaler J, Schwartz D, Gerhard WU, Weigert MG.
V region gene usage and somatic mutation in the primary and secondary
responses to influenza virus hemagglutinin. J Immunol 1990;144:2795-801.

21\. Rosner MH, Vigano MA, Ozato K, Timmons PM, Poirier F, Rigby PWJ,
Staudt LM. A POU-domain transcription factor in early stem cells and
germ cells of the mammalian embryo. Nature 1990;345:686-692.

22\. Kavaler J, Caton AJ, Staudt LM, Schwartz D, Gerhard W. A set of
closely related antibodies dominates the primary antibody response to
the antigenic site CB of the A/PR/8/34 influenza virus hemagglutinin. J
Immunol 1990;145:2312-21.

23\. Clarke S, Rickert R, Wloch MK, Staudt L, Gerhard W, Weigert M. The
BALB/c secondary response to the Sb site of influenza virus
hemagglutinin. J Immunol 1990;145:2286-96.

24\. Staudt LM, Lenardo MJ. Immunoglobulin gene transcription. Annu Rev
Immunol 1991;9:373-98.

25\. Siracusa LD, Rosner MH, Vigano MA, Gilbert DJ, Staudt LM, Copeland
NG, Jenkins NA. Chromosomal location of the octamer transcription
factors, Otf-1, Otf-2, and Otf-3, suggests close linkage to several
mutant loci and defines multiple Otf-3-related sequences dispersed in
the mouse genome. Genomics 1991;10:313-26.

26\. Caton AJ, Stark SE, Kavaler J, Staudt LM, Schwartz D, Gerhard W.
Many variable region genes are utilized in the antibody response of
BALB/c mice to the influenza virus A/PR/8/34 hemagglutinin. J Immunol
1991;147:1675-86.

27\. Kavaler J, Caton AJ, Staudt LM, Gerhard W. A B cell population that
dominates the primary response to influenza virus hemagglutinin does not
participate in the memory response. Eur J Immunol 1991;21:2687-95.

28\. Kang S-M, Tsang W, Doll S, Scherle P, Ko H-S, Tran A-C, Lenardo MJ,
Staudt LM. Induction of the POU domain transcription factor Oct-2 during
T-cell activation by cognate antigen. Mol Cell Biol 1992;12:3149-3154.

29\. Scherle P, Behrens T, Staudt LM. LyGDI, a GDP dissociation
inhibitor of the rhoA GTP-binding protein, is expressed preferentially
in lymphocytes. Proc Natl Acad Sci USA 1993;90:7568-72.

30\. Behrens TW, Jagadeesh J, Scherle P, Kearns G, Yewdell J, Staudt LM.
Jaw 1, a lymphoid-restricted membrane protein localized to the
endoplasmic reticulum. J Immunol 1994;153:682-690.

31\. Staudt LM, Dent A, Ma C, Allman D, Powell J, Maile R, Scherle P,
Behrens T. Rapid identification of novel human lymphoid-restricted genes
by automated DNA sequencing of subtracted cDNA libraries. Curr Topics
Microbiol Immunol 1994;194:155-161.

32\. Stewart DM, Notarangelo LD, Kurman CC, Staudt LM, Nelson DL.
Molecular genetic analysis of X-linked agammaglobulinemia with isolated
growth hormone deficiency. In: Caragol I, Espanol T, Fontan G, Matamoros
N, eds. Progress in immune deficiency V. Proc of European group for
immunodeficiencies. Barcelona: Springer-Verlag Ibérica 1995;52-54.

33\. Stewart DM, Notarangelo LD, Kurman CC, Staudt LM, Nelson DL.
Molecular genetic analysis of X-linked hypogammaglobulinemia and
isolated growth hormone deficiency. J Immunol 1995;155:2770-2774.

34\. Vigano MA, Staudt LM. Transcriptional activation by Oct-3. Evidence
for a specific role of the POU-specific domain in mediating functional
interaction with Oct-1. Nucl Acids Res 1996;24:2112-2118.

35\. Sorbara LR, Maldarelli F, Chamoun G, Schilling B, Chokekijcahi S,
Staudt L, Mitsuya H, Simpson IA, Zeichner SL. Human immunodeficiency
virus type 1 infection of H9 cells induces increased glucose transporter
expression. J Virol 1996; 70:7275-7279.

36\. Thornton AM, Ogryzko VV, Dent A, Sharf R, Levi B-Z, Kanno Y, Staudt
LM, Howard BH, Ozato K. A dominant negative mutant of an IFN regulatory
factor family protein inhibits both type I and type II IFN-stimulated
gene. J Immunol 1996;157:5145-5154.

37\. Behrens TW, Kearns G, Rivard JJ, Bernstein H, Yewdell J, Staudt LM.
Carboxy-terminal targeting and novel post-translational processing of
JAW1, a lymphoid protein of the endoplasmic reticulum. J Biol Chem
1996;271:23528-23534.

38\. Dent A, Yewdell J, Puvion-Dutilleul F, Koken MHM, de Thé H, Staudt
LM. LYSP100-associated nuclear domains (\"LANDS\"): A new class of
sub-nuclear structures and their relationship to PML nuclear bodies.
Blood 1996;88:1423-1436.

39\. Ma C, Staudt LM. LAF-4 encodes a lymphoid nuclear protein with
transactivation potential that is homologous to AF-4, the gene fused to
MLL in t(4,11) leukemias. Blood 1996;87:734-745.

40\. Liao X, Ma C, Trask B, Massa H, Gilbert DJ, Staudt LM, Jenkins NA,
Copeland NG. LAF4 maps to mouse chromosome 1 and human chromosome
2q11.2-q12. Mamm Genome 1996; 7:467-468.

41\. Allman D, Jain A, Dent A, Maile R, Selvaggi T, Kehry MR, Staudt LM.
BCL-6 expression during B cell activation. Blood 1996;87:5257-5268.

42\. Seyfert V, Allman D, He Y, Staudt LM. Transcriptional repression by
the proto-oncogene BCL-6. Oncogene 1996;12:2331-2342.

43\. Liao X, Gilbert DJ, Dent A, Staudt LM, Jenkins NA, Copeland, NG.
Mapping of the mouse Bcl6 gene to chromosome 16. Mamm Genome
1996;7:621-622.

44\. Dent AL, Shaffer A, Yu X, Allman D, Staudt LM. Control of
inflammation, cytokine expression and germinal center formation by
BCL-6. Science 1997;276:589-592.

45 Yin L, Arnheiter H, Scharton-Kersten TM, Schwartzberg P, Sher A,
Staudt LM, Lenardo M. Immune responses in mice deficient in Ly-GDI, a
lymphoid-specific regulator of rho GTPases. Mol Immunol. 1997;
34:481-491.

46 Dent AL, Hu-Li J, Paul WE, Staudt LM. TH2-type Inflammation in the
Absence of IL-4 and STAT6. Proc Natl Acad Sci, 1998; 95:13823-13828.

47 Alizadeh A, Eisen M, Brown PO, Staudt LM. Probing Lymphocyte Biology
by Genomic-scale Gene Expression Analysis. J Clin Immunol,
1998;18:373-379.

48 Iyer, VR, Eisen, MD, Ross, DT, Schuler, G, Moore, T, Lee, J, Trent,
JM, Staudt, LM, Hudson, J, Boguski, M, Lashkari, D, Shalon, D, Botstein,
D, Brown, PO The transcriptional response of human fibroblasts to serum.
Science 1999;283:83-87.

49 Dent AL, Shaffer A, Yu X, Staudt LM. Regulation of Lymphocyte Cell
Fate Decisions and Lymphomagenesis by BCL-6. Int Rev Immunol
1999;18:381-403.

50 Carter KC, Annunziata CM, Barash S, Staudt LM, Dillon PJ, Fergusso,
M, Rosen CA, Cossman J. Reed-Sternberg cell genome expression. Blood,
1999; 94:411-416.

51 Dent AL, Doherty, TM, Paul WE, Sher, A, Staudt LM. BCL-6-deficient
mice reveal an IL-4-independent STAT6-dependent pathway that controls
susceptibility to infection by Leishmania major. J Immunol 1999;
163:2098-2103.

52 Cossman J, Staudt LM, Raffeld M. Application of molecular genetics to
the diagnosis of hematopoietic neoplasms. In Neoplastic Hematopathology,
DM Knowles, Ed., 1999.

53 Alizadeh A, Eisen M, Davis RE, Ma CA, Sabet H, Tran T, Powell JI,
Yang L, Marti GE, Moore DT, Hudson JR, Chan WC, Greiner T, Weisenberger
D, Armitage JO, Lossos I, Levy R, Botstein D, Brown PO, Staudt LM. The
Lymphochip: A specialized cDNA microarray for the genomic-scale analysis
of gene expression in normal and malignant lymphocytes. Cold Spring
Harbor Symposium on Quantitative Biology, 1999; 64:71-78.

54 Staudt LM. The molecular and cellular origins of Hodgkin\'s disease.
J Exp Med, 2000; 191:207-212

55 Alizadeh A, Eisen M, Davis RE, Ma CA, Lossos I, Rosenwald A, Boldrick
J, Sabet H, Tran T, Yu X, Powell J, Yang L, Marti G, Moore T, Hudson J,
Chan WC, Greiner TC, Weissenberger DD, Armitage JO, Levy R, Grever MR,
Byrd JC, Botstein D, Brown PO, Staudt LM. Distinct types of diffuse
large B-cell lymphoma identified by gene expression profiling. Nature
2000; 403:503-511.

56 Alizadeh AA, Staudt LM. Genomic-scale gene expression profiling of
normal and malignant immune cells. Curr Opin Immunol 2000, 12:219-225.

57 Staudt LM. The expression of the genome during immune responses. Curr
Opin Immunol 2000, 12:199-200.

58 Staudt LM, Brown PO. Genomic views of the immune system. Annual
Review of Immunology, 2000, 18:829-859.

59 Hastie T, Tibshirani R, Eisen MB, Alizadeh A, Levy R, Staudt L, Chan
WC, Botstein D, Brown P. 'Gene shaving' as a method for identifying
distinct sets of genes with similar expression patterns. Genome Biology
2000, 1:3.1-3.21.

60 Lossos IS, Alizadeh AA, Eisen MB, Chan WC, Brown PO, Botstein D,
Staudt LM, Levy R. Ongoing immunoglobulin heavy chain somatic mutation
in germinal center B cell-like but not in activated B cell-like diffuse
large cell lymphomas. Proc Natl Acad Sci 2000, 97:10209-10213.

61 Meffre E, Davis E, Schiff C, Cunningham-Rundles C, Ivashkiv LB,
Staudt LM, Young JW, Nussenzweig MC. Circulating human B cells that
express surrogate light chains and edited receptors. Nature Immunology
2000, 3:207-213.

62 Shaffer AL, Yu X, He Y, Boldrick J, Chan E, Staudt LM. BCL-6
represses genes that function in lymphocyte differentiation,
inflammation and cell cycle control. Immunity 2000, 13:199-212.

63 Ma C, Staudt LM. Molecular definition of the germinal centre stage of
B cell differentiation. Phil. Trans. R. Soc. Lond. B 2001, 356:83-89.

64 Feske S, Giltnane J, Dolmetsch R, Staudt LM, Rao A. Gene regulation
mediated by calcium signals in T lymphocytes. Nature Immunology 2001,
2:316-324.

65 Staudt LM. Gene expression physiology and pathophysiology of the
immune system. Trends in Immunology 2001, 22:35-40.

66 Boehm J, He Y, Greiner A, Staudt L, Wirth T. Regulation of
BOB.1/OBF.1 stability by SIAH. EMBO J. 2001, 20:4153-4162.

67 Wandinger K-P, Sturzebecher C-S, Bielekova B, Detore G, Rosenwald A,
Staudt LM, McFarland HF, Martin R. Complex immunomodulatory effects of
interferon-beta in multiple sclerosis include the upregulation of T
helper 1-associated marker genes. Ann Neurol 2001, 50:349-357.

68 Siebert R, Rosenwald A, Staudt LM, Morris S. Molecular features of
B-cell lymphoma. Current Opinion in Oncology 2001, 13:316-324.

69 Shaffer AL, Rosenwald A, Hurt E, Giltnane J, Lam L, P:ickeral O,
Staudt LM. Signatures of the immune response. Immunity 2001, 15:375-385.

70 Staudt LM, Flavell RA. Genomics, genetics and genes of the immune
system. Immunity 2001, 15:335-336.

71 Lam L, Pickeral OK, Davis RE, Giltnane J, Sathyamoorthy M, Yu X,
Rosenwald A, Hurt E, Shaffer AL, Hollingshead M, Harris E, Monks A,
Milovits J, Sausville E, Staudt LM. Genomic-scale measurement of mRNA
turnover using the anti-cancer drug flavopiridol. Genome Biology 2001,
2:0041.1-0041.11.

72 Rosenwald A, Alizadeh AA, Widhopf, GF, Simon R, Davis RE, Yu X, Yang
L, Pickeral OK, Rassenti LZ, Powell J, Botstein D, Byrd JC, Grever MR,
Cheson BD, Chiorazzi N, Wilson WH, Kipps TJ, Brown PO, Staudt, LM.
Relation of gene expression phenotype to immunoglobulin mutation
genotype in B-cell chronic lymphocytic leukemia. Journal of Experimental
Medicine 2001, 194:1639-1647.

73 Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive NF-kB
activity is required for survival of activated B-like diffuse large
B-cell lymphoma cells. Journal of Experimental Medicine 2001,
194:1861-1874.

74 Staudt LM. Gene expression profiling of lymphoid malignancies. Annual
Review of Medicine 2002, 53:303-318.

75 Boldrick JC, Alizadeh AA, Diehn M, Dudoit S, Liu CL, Belcher CE,
Botstein D, Staudt LM, Brown PO, Relman DA. Stereotyped and specific
gene expression programs in human innate immune responses to bacteria.
Proc Natl Acad Sci 2002, 99:972-977.

76 Huang JZ, Pickering, DL, Sanger WG, Staudt LM, Greiner TC,
Weisenburger DD, Armitage JO, Warnke RA, Levy R, Wu G, Lynch, JC, Chan
WC. The t(14;18) defines a unique subset of diffuse large B-cell
lymphoma (DLBCL) with a germinal center B-cell gene expression profile.
Blood 2002, 99:2285-2290.

77 Rosenwald A, Staudt LM. Clinical translation of gene expression
profiling in lymphomas and leukemias. Seminars in Oncology 2002,
29:258-63.

78 Wilson WH, Grossbard ML, Pittaluga S, Cole D, Pearson D, Drbohlav N,
Steinberg SM, Little RF, Janik J, Gutierrez M, Raffeld M, Staudt LM,
Cheson, BD Longo DL, Harris N, Jaffe ES, Chabner BA, Wittes R, Balis F.
Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a
pharmacodynamic approach with high efficacy. Blood 2002, 99:2685-2693.

79 Davis RE, Staudt LM. Molecular diagnosis of lymphoid malignancies by
gene expression profiling. Current Opinion in Hematology 2002, 9:333-8.

80 Staudt LM. It's ALL in the diagnosis. Cancer Cell 2002, 1:109-110.

81 Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI,
Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao
H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell
J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ,
Lynch JC, Vose J, Armitage JO, Montserrat E, Lopez-Guillermo A, Grogan
TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P,
Stokke T, Staudt LM. The use of molecular profiling to predict survival
after chemotherapy of diffuse large B-cell lymphoma. N Engl J Med
2002,346:1937-1947.

82 Shaffer AL, Lin K--I, Yu X, Hurt EM, Rosenwald A, Giltnane JM, Zhao
H, Calame K, Staudt LM. Blimp-1 orchestrates plasma cell differentiation
by extinguishing the mature B cell gene expression program. Immunity,
2002, 17:51-62.

83 Shaffer AL, Rosenwald A, Staudt LM. Lymphoid malignancies: the dark
side of mature B cell differentiation and activation. Nature Reviews
Immunology 2002, 2:1-13.

84 Staudt LM, Wilson WH. Focus on lymphoma. Cancer Cell 2002, 2:363-366.

85 Kalaitzidis D, Davis RE, Rosenwald A, Staudt LM, Gilmore TD. The
human B-cell lymphoma cell line RC-K8 has multiple genetic alterations
that dysregulate the Rel/NF-kB signal transduction pathway. Oncogene
2002, 21:8759-68.

86 Kovanen P, Rosenwald A, Fu J, Hurt EM, Lam LT, Giltnane JM, Wright G,
Staudt LM, Leonard W. Analysis of γc-family cytokine target genes:
Identification of DUSP5 as a regulator of MAP kinase activity in IL-2
signaling. J Biol Chem 2003, 278:5205-5213.

87 Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E,
Gascoyne RD, Grogan TM, Muller-Hermelink HK, Smeland EB, Chiorazzi M,
Giltnane JM, Hurt EM, Zhao H, Averett L, Henrickson S, Yang L, Powell J,
Wilson WH, Jaffe ES, Simon R, Klausner RD, Montserrat E, Bosch F,
Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J,
Armitage JO, Fisher RI, Miller TP, LeBlanc M, Ott G, Kvaloy S, Holte H,
Delabie J, Staudt LM. The proliferation gene expression signature is a
quantitative integrator of oncogenic events that predicts survival in
mantle cell lymphoma. Cancer Cell, 2003, 3:185-197.

88 Nasr R, Rosenwald A, El-Sabban ME, Arnulf B, Zalloua P, Lepelletier
Y, Bex F, Hermine O, Staudt L, de The H, Bazarbachi A.
Arsenic/interferon specifically reverses two distinct gene networks
critical for the survival of HTLV-I infected leukemic cells. Blood 2003,
101:4576-82.

89 Sanchez-Izquierdo D, Buchonnet G, Siebert R, Gascoyne RD, Climent J,
Karran EL, Marin M, Blesa D, Horsman D, Rosenwald A, Staudt LM,
Albertson DG, Du MQ, Ye H, Marynen P, Garcia-Conde J, Pinkel P,

Dyer MJS, Martinez-Climent JA. MALT1 is deregulated by both chromosomal
translocation and amplification in B-cell non-Hodgkin lymphoma. Blood
2003, 101:4539-46.

90 Sturzebecher S, Wandinger KP, Rosenwald A, Sathyamoorthy M, Tzou A,
Mattar P, Frank JA, Staudt L, Martin R, McFarland HF. Expression
profiling identifies responder and non-responder phenotypes to
interferon-beta in multiple sclerosis. Brain. 2003, 126:1419-1429.

91 Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE,
Zhao H, Ibbotson RE, Orchard JA, Davis Z, Stetler-Stevenson M, Raffeld
M, Arthur DC, Marti GE, Wilson WH, Hamblin TJ, Oscier DG, Staudt LM.
ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with
unmutated immunoglobulin genes, inferior clinical outcome and distinct
gene expression profile. Blood, 2003, 101:4944-4951.

92 Pan Z, Shen Y, Du C, Zhou G, McKeithan T, Rosenwald A, Staudt L, Chan
WC. Two newly characterized germinal center B-cell associated genes that
have diagnostic and prognostic values in B-cell lymphoproliferative
disorders. Am J Pathol, 2003, 163:135-44.

93 Wright GE, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM. A gene
expression-based method to diagnose clinically distinct subgroups of
diffuse large B cell lymphoma. Proc Natl Acad Sci 2003, 100:9991-9996.

94 Staudt LM. Molecular diagnosis of the hematologic cancers. N Engl J
Med 2003 348:1777-85.

95 Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, Chan
WC, Zhao H, Haioun C, Greiner TC, Weisenburger DD, Lynch JC, Vose J,
Armitage JO, Smeland EB, Kvaloy S, Holte H, Delabie J, Campo E,
Montserrat E, Lopez-Guillermo A, Ott G, Muller-Hermelink HK, Connors JM,
Braziel1 R, Grogan TM, Fisher RI, Miller TP, LeBlanc M, Chiorazzi M,
Zhao H, Yang L, Powell J, Wilson WH, Jaffe ES, Simon R, Klausner RD,
Staudt LM. Molecular diagnosis of primary mediastinal B cell lymphoma
identifies a clinically favorable subgroup of diffuse large B cell
lymphoma related to Hodgkin lymphoma. J Exp Med 2003, 198:1-12.

96 Orchard JA, Ibbotson RE, Davis Z, Wiestner A, Rosenwald A, Thomas PW,
Hamblin TJ, Staudt LM, Oscier DG. ZAP-70 expression by flow cytometry is
a good prognostic marker in CLL and a potential surrogate for
immunoglobulin VH gene mutations. Lancet 2004, 363:105-111.

97 Wiestner A, Staudt LM. Towards Molecular Diagnosis and Targeted
Therapy of Lymphoid Malignancies. Sem Hematol 2003, 40:296-307.

98 McConnell MJ, Chevallier N, Berkofsky-Fessler W, Giltnane JM, Malani
RB, Staudt LM, Licht JD. Growth suppression by acute promyelocytic
leukemia-associated PLZF is mediated by repression of c-myc expression.
Mol Cell Biol 2003, 23:9375--9388.

99 Rosenwald A, Staudt LM. Gene expression profiling of diffuse large
B-cell lymphoma. Leukemia and Lymphoma 2003 Suppl. 3 44:S41-S47.

100 Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J,
Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P,
Smith LM, Lynch JC, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors
JM, Armitage JO, Chan WC. Molecular subclassification of diffuse large
B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood
2004 103:275-82.

101 Weller S, Tan B, Rosenwald A, Braun MC, Cordier C, Conley M-E,
Plebani A, Kumararatne DS, Bonnet D, Tournilhac O, Tchernia G, Staudt
LM, Casanova J-L, Reynaud C-A, Weill J-C. Circulating IgM "memory" and
splenic marginal zone B cells in humans define a unique B cell
population. Blood 2004 104:3647-54.

102 Rosenwald A, Chuang EY, Davis RE, Wiestner A, Alizadeh AA, Botstein
D, Brown PO, Mitchell JB, Marti GE, Fowler DH, Wilson WH, Staudt LM.
Fludarabine treatment of chronic lymphocytic leukemia patients induces a
p53-dependent gene expression response. Blood 2004 104:1428-1434.

103 Cahir-McFarland ED, Carter K, Rosenwald A, Giltnane J, Henrickson S,
Staudt LM, Kieff E. Role of EBV latency III, LMP1 and NF-kB in cell
survival and gene expression. J Virol 2004 78:4108-4119.

104 Rimsza L, Roberts RA, Miller TP, Unger JM, LeBlanc M, Braziel R,
Weisenburger DD, Chan WC, Greiner TP, Muller-Hermelink K, Jaffe ES,
Gascoyne RD, Campo E, Fuchs D, Spier CM, Fisher RI, Staudt LM, Grogan T.
Loss of MHC class II gene and protein expression in diffuse large B cell
lymphoma is related to decreased tumor immunosurveillance and poor
patient survival: A follow-up study to the NIH Director\'s Challenge
Leukemia and Lymphoma Molecular Profiling Project. Blood 2004
103:4251-4258.

105 Rosenwald A, Staudt LM, Duyster JG, Morris SW. Molecular aspects of
non-Hodgkin lymphomagenesis. In Wintrobe's Clinical Hematology 2004.

106 Nimmerjahn F, Dudziak D, Dirmeier U, Hobom G, Riedel A, Schlee M,
Staudt LM, Rosenwald A, Behrends U, Bornkamm GW, Mautner J. Active
NF-{kappa}B signalling is a prerequisite for influenza virus infection.
J Gen Virol. 2004 85:2347-2356.

107 Iqbal J, Sanger WG, Horsman DE, Rosenwald A, Pickering DL, Dave S,
Cao K, Zhu Q, Xiao L, Sherman S, Hans CP, Weisenburger DD, Greiner TC,
Gascoyne RD, Ott G, Müller-Hermelink HK, Delabie J, Braziel RM, Jaffe
ES, Campo E, Lynch JC, Connors JM, Vose JM, Armitage JO, Grogan T,
Staudt LM, Chan WC. BCL2 translocation defines a subset of DLBCL with
germinal center B-cell-like gene expression profiles and preferential
expression of a set of genes. Am J Pathol 2004 165:159-66.

108 Tunyaplin C, Shaffer AL, Angelin-Duclos CD, Yu X, Staudt LM, Calame
KL. Direct Repression of *prdm1* by Bcl-6 Inhibits Plasmacytic
Differentiation. J Immunol 2004 173:1158-65.

109 Shen Y, Iqbal J, Xiao L, Lynch RC, Rosenwald A, Staudt LM, Sherman
S, Dybkaer K, Zhou G, Eudy JD, Delabie J, McKeithan TW, Chan WC.
Distinct gene expression profiles in different B-cell compartments in
human peripheral lymphoid organs. BMC Immunlogy, 2004 5:20.

110 Shaffer AL, Shapiro-Shelef M, Iwakoshi NN, Lee A-H, Qian S-B, Zhao
H, Yu X, Yang L, Tan BK, Rosenwald A, Hurt EM, Petroulakis E, Sonenberg
N, Yewdell JW, Calame K, Glimcher LH, Staudt LM. XBP acts downstream of
Blimp- to expand the secretory apparatus, promote organelle biogenesis,
and increase protein synthesis during plasma cell differentiation.
Immunity 2004, 21:81:93.

111 DeLeeuw RJ, Davies JJ, Rosenwald A, Bebb G, Gascoyne RD, Dyer MJ,
Staudt LM, Martinez-Climent JA, Lam WL. Comprehensive whole genome array
CGH profiling of mantle cell lymphoma model genomes.

Hum Mol Genet. 2004, 13:1827-37.

112 Hurt EM, Wiestner A, Rosenwald A, Campo E, Grogan T, Bergsagel PL,
Kuehl WM, Staudt LM. Overexpression of c-maf is a frequent oncogenic
event in multiple myeloma that promotes proliferation and pathological
interactions with bone marrow stroma. Cancer Cell 2004 5:191-199.

113 Staudt LM. Negative feedback for B cells. Nature 2004 431:919-920.

114 Dave S, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher
RI, Braziel R, Grogan TM, Miller TP, LeBlanc M, Greiner TC, Weisenburger
DD, Lynch JC, Vose J, Armitage JO, Smeland EB, Kvaloy S, Holte H,
Delabie J, Connors JM, Lansdorp P, Ouyang Q, Lister TA, Davies AJ,
Norton AJ, Muller-Hermelink HK, Ott G, Campo E, Montserrat E, Wilson WH,
Jaffe ES, Simon R, Yang L, Powell J, Zhao H, Goldschmidt N, Chiorazzi M,
Staudt LM. Survival following diagnosis of follicular lymphoma is
predicted by molecular features of non-malignant tumor-infiltrating
immune cells. New Engl J Med 2004 351:2159-2169.

115 Lam LT, Davis RE, Pierce J, Hepperle M, Xu Y, Hottelet M, Nong Y,
Wen D, Adams J, Dang L, Staudt LM. Small molecule inhibitors of
IkB-Kinase are selectively toxic for subgroups of diffuse large B cell
lymphoma defined by gene expression profiling. Clinical Cancer Research
2005 11:1-13.

116 Ho L, Davis RE, Conne B, Chappuis R, Berczy M, Adam M, Mhawech P,
Staudt LM, Schwaller J. MALT and the API-MALT fusion act between CD and
IKK and confer NF-kB dependent proliferative advantage and resistance
against FAS-induced cell death in B cells. Blood 2005105:2891-2899.

117 Staudt LM. Molecular diagnosis of the lymphomas by gene expression
profiling. In: The Lymphomas. GP Canellos, TA Lister, B Young, editors.
2005, in press.

118 Staudt LM, Dave, S. The biology of human lymphoid malignancies
revealed by gene expression profiling. Advances in Immunology 2005,
87:163-208.

119 Petersen D, Chandramouli GVR , Geoghegan J, Hilburn J, Paarlberg J,
Kim CH, Munroe D, Gangi L, Han J, Puri R, Staudt L, Weinstein J, Barrett
JC, Green J, Kawasaki ES. Three microarray platforms: an analysis of
their concordance in profiling gene expression. BMC Genomics 2005, 6:63.

120 Rubio-Moscardo F, Blesa D, Mestre C, Siebert R, Balasas T, Benito A,
Rosenwald A, Climent J, Martinez JI, Schilhabel M, Karran EL, Gesk S,
Esteller M, deLeeuw R, Staudt LM Fernandez-Luna JL, Pinkel D, Dyer MJS,
Martinez-Climent JA. Characterization of 8p21.3 chromosomal deletions in
B-cell lymphoma: *TRAIL-R1* and *TRAIL-R2* as candidate dosage-dependent
tumor suppressor genes. Blood 2005 106:3214-22.

121 Mestre C, Rubio-Moscardo F, Rosenwald A, Climent J, Dyer MJ, Staudt
L, Pinkel D, Siebert R, Martinez-Climent JA. Homozygous deletion of
SOCS1 in primary mediastinal B-cell lymphoma detected by CGH to BAC
microarrays. Leukemia 2005 19:1082-4.

122 Bea S, Zettl A, Wright G, Salaverria I, Jehn J, Moreno V, Burek C,
Ott G, Puig X, Yang L, Lopez-Guillermo A, Chan WC, Greiner TC,
Weisenburger DD, Armitage JO, Gascoyne RD, Connors JM, Grogan TM,
Braziel R, Fisher RI, Smeland EB, Kvaloy S, Delabie J, Simon R, Powell
J, Wilson WH, Jaffe ES, Montserrat E, Muller-Hermelink HK, Staudt LM,
Campo E, Rosenwald A. Diffuse large B cell lymphoma subtypes have
distinct genetic profiles that influence tumor biology and improve gene
expression-based survival prediction. Blood 2005 106:3183-90.

123 Fu K, Weisenburger DD, Greiner TC, Dave S, Chiorazzi M, Wright G,
Gesk S, Siebert R, De Jong D, Jaffe ES, Delabie J, Ott G, Wilson W,
Braziel RM, Dave BJ, Sanger WG, Smith LM, Müller-Hermelink HK, Campo E,
Gascoyne RD, Rosenwald A, Staudt LM, Chan WC. Cyclin D1-negative mantle
cell lymphoma: A gene expression profiling, genetic and
clinicopathological study. Blood 2005106:4315-21.

124 Park SS, Shaffer AL, Kim JS, duBois W, Potter M, Staudt LM, Janz S.
Insertion of *Myc* into *Igh* accelerates peritoneal plasmacytomas in
mice. Cancer Research 2005 65:7644-7652.

125 Han S-S, Shaffer AL, Peng L, Chung S-T, Lim J-H, Maeng S, Kim JS,
McNeil N, Ried T, Staudt LM, Janz S. Molecular and cytological features
of the mouse B-cell lymphoma line iMycEm-1. Mol Cancer 2005 4:40.

126 Greiner TC, Dasgupta C, Ho VV, Weisenburger DD, Smith LM, Lynch JC,
Vose JM, Armitage JO, Braziel RM, Campo E, Delabie J, Gascoyne RD, Jaffe
ES, Muller-Hermelink HK, Ott G, Rosenwald A, Staudt LM, Im MY, Karaman
MW, Pike BL, Chan WC, Hacia JG. Mutation and genomic deletion status of
*ATM* and *p53* confer specific gene expression profiles in mantle cell
lymphoma. Proc Natl Acad Sci 2006 103:2352-7.

127 Rimsza LM, Roberts RA, Campo E, Grogan TM, Bea S, Salaverria I,
Zettl A, Rosenwald A, Ott G, Muller-Hermelink K, Delabie J, Fisher RI,
Unger JM, Leblanc M, Staudt LM, Jaffe ES, Gascoyne RD, Chan WC,
Weinsenberger DD, Greiner TC, Braziel RM, Miller TP. Loss of major
histocompatibility class II expression in non-immune privileged site
diffuse large B cell lymphoma is highly coordinated and not due to
chromosomal deletions. Blood 2006 107:1101-7.

128 Iqbal J, Neppalli VT, Wright G , Dave B, Horsman DE, Rosenwald A, Fu
K, Pickering DL, Lynch J, Hans CP, Weisenburger DD, Greiner TC, Gascoyne
RD, Campo E, Ott G, Müller-Hermelink HK, Delabie J, Jaffe ES, Braziel
RM, Grogan TM, Connors JM, Yulei S, Sanger WG, Vose JM, Armitage JO,
Staudt LM, Chan WC. BCL2 expression is a prognostic marker for the
activated B-cell-like type of diffuse large B-cell lymphoma. J Clin
Oncol 2006 24:961-8.

129 Spence SL, Shaffer AL, Staudt LM, Amde S, Manney S, Terry C, Weisz
K, Nissley P. Transformation of Late Passage Insulin-Like Growth
Factor-I Receptor Null Mouse Embryo Fibroblasts by SV40 T Antigen.

Cancer Res. 2006 66:4233-9.

130 Roberts RA, Wright G, Rosenwald A, Jaramillo MA, Grogan TM, Miller
TP, Frutiger Y, Chan WC, Gascoyne RD, Ott G, Muller-Hermelink HK, Staudt
LM, Rimsza LM. Loss of MHC Class II gene and protein expression in
primary mediastinal large B cell lymphoma is highly coordinated and
related to poor patient survival. Blood 2006 108:311-8.

131 Liu H, Ippolito GC, Wall JK, Niu T, Probst L, Lee BS, Pulford K,
Banham A, Stockwin L, Shaffer AL, Staudt LM, Das C, Dyer MJ, Tucker PW.
Functional studies of BCL11A: Characterization of the conserved
BCL11A-XL splice variant and its interaction with BCL6 in nuclear
paraspeckles of germinal center B cells. Mol Cancer 2006 5:18.

132 Sciammas R, Shaffer AL, Schatz JH, Zhao H, Staudt LM, Singh H.
Graded expression of Interferon Regulatory Factor-4 coordinates isotype
switching with plasma cell differentiation. Immunity 2006 25: 225-36.

133 Shaffer AL, Wright GW, Yang L, Ngo V, Lamy L, Lam L, Davis RE,
Staudt LM. A library of gene expression signatures to illuminate normal
and pathological lymphoid biology. Immunol Rev 2006 210:67-85.

134 Dave SS, Fu K, Wright G, Lam LT, Kluin P, Boerma E-J, Greiner TC,
Weisenburger DD, Rosenwald,A Ott G, Muller-Hermelink HK, Gascoyne RD,
Delabie J, Rimsza LM, Braziel RM, Grogan TM, Campo E, Jaffe ES, Dave BJ,
Sanger W, Bast M, Vose JM, Armitage JO, Connors JM, Smeland EB, Kvaloy
S, Holte H, Fisher RI, Miller TP, Montserrat E, Wilson WH, Bahl M, Zhao
H, Yang L, Powell J, Simon R, Chan WC, Staudt LM. Molecular diagnosis of
Burkitt's lymphoma. New Engl J Med 2006 354:2431-2442.

135 Ngo VN, Davis RE, Lamy L, Yu X, Zhao H, Lenz G, Lam L, Dave S, Yang
L, Powell J, Staudt LM. A loss-of-function RNA interference screen for
molecular targets in cancer. Nature 2006 441:106-110.

136 Schlee M, Hölzel M, Bernard S, Mailhammer R, SchuhmacherM, Reschke
J, Eick D, MarinkovicD, Wirth T, Rosenwald A, Staudt LM, Eilers M,
Baran-Marszak F, Fagard R, Feuillard J, Laux G, and Bornkamm GW. c-MYC
activation impairs the NF-kB and the interferon response: implications
for the pathogenesis of Burkitt's lymphoma. Int J Cancer 2007
120:1387-95.

137 Cuadros M, Dave S, Jaffe ES, Honrado E, Milne R, Alves J, Rodríguez
J, Zajac M, Benitez J, Staudt LM, Martinez-Delgado B. Identification of
a proliferation signature related to survival in nodal peripheral T cell
lymphomas. J Clin Oncol 2007 25:3321-9.

138 Davis RE, Zhang Y-Q, Southall N, Inglese J, Staudt LM, Austin C,
Auld DS. A cell-based assay for IkappaBalpha stabilization using a
two-color dual luciferase-based sensor. Assay Drug Dev Technol 2007
5:85-103.

139 Young KH, Weisenburger DD, Dave B, Smith L, Sanger W, Iqbal J, Campo
C, Delabie J, Gascoyne RD, Ott G, Rimsza L, Müeller-Hermelink HK, Jaffe
ES, Rosenwald A, Staudt LM, Chan WC, Greiner TC. Mutations in the
DNA-Binding Codons of *TP53,* Which are Associated with Decreased
Expression of TRAIL Receptor-2, Predict for Poor Survival in Diffuse
Large B-cell Lymphoma. Blood 2007 110:4396-405.

140 Davies AJ, Rosenwald A, Wright G, Lee A, Chiorazzi M, Zhao H, Last
KW, Weisenburger DD, Chan WC, Delabie J, Braziel RM, Campo E, Gascoyne
RD, Jaffe ES, Muller-Hermelink HK, Ott G, Calaminici M, Norton AJ, Goff
LK, Fitzgibbon J, Staudt LM and Lister TA. Transformation of follicular
lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic
mechanisms. Br J Hematol 2007 136:286-93.

141 Hystad ME, Myklebust JH, Bø TH, Sivertsen EA, Rian E, Forfang L,
Munthe E, Rosenwald A, Chiorazzi M, Jonassen I, Staudt LM, Smeland EB.
Characterization of early human B cell development by gene expression
profiling. J Immunol 2007 179:3662-71.

142 Kimm LR, deLeeuw RJ, Savage KJ, Rosenwald A, Campo E, Delabie J, Ott
G, Muller-Hermelink HK, Jaffe ES, Rimsza LM, Weisenburger DD, Chan WC,
Staudt LM, Connors JM, Gascoyne RD, Lam WL. Frequent occurrence of
deletions in primary mediastinal B-cell lymphoma. Genes Chromosomes
Cancer 2007 46:1090-7.

143 Han SS, Davis RE, Kim KH, Staudt LM, Janz S. Constitutive NFκB
activity is essential in mouse iMyc^Eμ^ B-cell lymphoma and maintains
Myc protein levels. 2007, submitted.

144 Mestre-Escorihuela C, Rubio-Moscardo F, Richter JA, Siebert R,
Climent J, Fresquet V, Beltran E, Agirre X, Marugan I, Marin M,
Rosenwald A, Sugimoto KJ, Wheat LM, Karran EL, Garcia JF, Sanchez L,
Prosper F, Staudt LM, Pinkel D, Dyer MJS, Martinez-Climent JA.
Homozygous deletions localize novel tumor suppressor genes in B-cell
lymphomas. Blood 2007 109:271-80.

145 Dunleavy K, Davis RE, Landgren O, Staudt LM, Wilson WH. BCL-6 and
Rituximab in Diffuse Large B-cell Lymphoma: Where are we? Blood 2007
109:843-4.

146 Iqbal J, Greiner TC, Patel K, Dave BJ, Smith L, Ji J, Wright G,
Sanger WG, Pickering DL, Jain S, Horsman DE, Shen Y, Fu K, Weisenburger
DD, Hans CP, Campo E, Gascoyne RD, Rosenwald A, Jaffe ES, Delabie J,
Rimsza L, Ott G, Müller-Hermelink HK, Connors JM, Vose JM, McKeithan T,
Staudt LM Chan WC. Distinctive patterns of BCL6 molecular alterations
and their functional consequences in different subgroups of diffuse
large B-cell lymphoma. Leukemia 2007 21:2332-43.

147 Staudt L. A closer look at follicular lymphoma. New Engl J Med 2007
356:741-2.

148 Lenz G, Staudt LM. Pathobiology of Non-Hodgkin's Lymphoma. In
Hoffman\'s Hematology, Fifth Edition, 2007.

149 Salaverria I, Zettl A, Bea S, Valls J, Moreno V, Hartmann E, Ott G,
Wright G, Jehn P, Puig X, Yang L, Lopez-Guillermo A, Chan WC, Greiner
TC, Weisenburger DD, Armitage JO, de Jong D, Gascoyne RD, Connors JM,
Grogan TM, Rimsza LM, Braziel R, Fisher RI, Smeland EB, Kvaloy S, Holte
H, Delabie J, Simon R, Powell J, Wilson WH, Jaffe ES, Montserrat E,
Muller-Hermelink H-K, Staudt LM, Rosenwald A, Campo E. Specific
secondary genetic alterations in mantle cell lymphoma provide prognostic
information independent of the gene expression-based proliferation
signature. J Clin Oncol 2007 25:1216-22.

150 Kuo TC, Shaffer AL, Haddad J, Choi YS, Staudt LM, Calame K.
Repression of BCL-6 is required for the formation of human memory B
cells in vitro. J Exp Med 2007 204:819-30.

151 Wan F, Anderson DE, Barnitz RA, Snow A, Bidere N, Zheng L, Hegde V,
Lam LT, Staudt LM, Levens D, Deutsch WA, Lenardo MJ. Ribosomal Protein
S3: a KH domain protein found in NF-kB complexes that mediates selective
gene regulation. Cell 2007 131:927-39.

152 Wiestner A, Tehrani M, Chiorazzi M, Wright G, Nakayama K, Liu H,
Rosenwald A, Muller-Hermelink HK, Ott G, Chan WC, Greiner TC,
Weisenburger DD, Vose J, Armitage JO, Gascoyne RD, Connors JM, Campo E,
Montserrat E, Bosch F, Smeland EB, Kvaloy S, Holte H, Delabie J, Fisher
RI, Grogan TM, Miller TP, Wilson WH, Jaffe ES, Staudt LM. Point
mutations and genomic deletions in the Cyclin D1 gene create stable
truncated mRNAs that are associated with increased proliferation rate
and shorter survival in mantle cell lymphoma. Blood 2007 109:4599-4606.

153 Lenz G, Nagel I, Siebert R, Roschke A, Sanger W, Wright GW, Dave SS,
Tan B, Zhao H, Rosenwald A, Muller-Hermelink HK, Gascoyne RD, Campo E,
Jaffe ES, Smeland EB, Fisher RI, Kuehl WM, Chan WC, Staudt LM. Aberrant
immunoglobulin class switch recombination and switch translocations in
activated B cell-like diffuse large B-cell lymphoma. J Exp Med 2007
204:633-43.

154 Annunziata CM, Davis RE, Demchenko Y, Gabrea A, Lenz G, Wright G,
Xiao W, Dave S, Zhao H, Hanamura I, Zhan F, Stephens O, Dang L, William
Bellamy, Bargolie B, Shaughnessy JD, Jr, Kuehl WM, Staudt LM. Frequent
engagement of the classical and alternative NF-kB pathways by diverse
genetic abnormalities promotes cell survival in multiple myeloma. Cancer
Cell 2007 12:115-130.

155 Wilson WH, Dunleavy K, Pittaluga S, Hegde U, Grant N, Steinberg SM,
Raffeld M, Gutierrez M, Chabner BA, Staudt L, Jaffe ES, Janik J. Phase
II study of dose-adjusted EPOCH and Rituximab in untreated diffuse large
B-cell lymphoma with analysis of germinal center and post-germinal
center biomarkers. J Clin Oncol 2008 26:2717-24.

156 Baskar S, Kwong KY, Hofer T, Levy JM, Kennedy MG, Lee E, Staudt LM,
Wilson WH, Wiestner A, Rader C. Unique cell surface expression of
receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic
leukemia. Clin Cancer Res 2008 14:396-404.

157 Xie Y, Deng S, Thomas CJ, Liu Y, Zhang YQ, Rinderspacher A, Huang W,
Gong G, Wyler M, Cayanis E, Aulner N, Többen U, Chung C, Pampou S,
Southall N, Vidović D, Schürer S, Branden L, Davis RE, Staudt LM,
Inglese J, Austin CP, Landry DW, Smith DH, Auld DS. Identification of
N-(quinolin-8-yl)benzenesulfonamides as agents capable of
down-regulating NFkappaB activity within two separate high-throughput
screens of NFkappaB activation. Bioorg Med Chem Lett 2008 18:329-35.

158 Salaverria I, Zettl A, Beà S, Dave S, Wright G, Hartmann EM, Boerma
EG, Kluin PM, Ott G, Chan WC, Lopez-Guillermo A, Gascoyne RD, Delabie J,
Rimsza L, Braziel R, Jaffe ES, Staudt LM, Müller-Hermelink HK, Campo E,
Rosenwald A. Chromosomal alterations detected by comparative genomic
hybridization (CGH) in subgroups of gene expression-defined Burkitt
lymphoma. Hematologica 2008, in press.

159 Young KH, Leroy K, Møller MB, Colleoni GWB, Sánchez-Beato M, Kerbauy
FR, Haioun C, Eickhoff JC, Young AH, Gaulard P, Piris MA, Oberley TD,
Rehrauer WM, Kahl BS, Malter JS, Campo E, Delabie J, Gascoyne RD,
Rosenwald A, Rimsza L, Huang J, Braziel RM, Jaffe ES, Wilson WH, Staudt
LM, Vose JM, Chan WC, Weisenburger DD, Greiner TC. Structural profiles
of TP53 gene mutations predict clinical outcome in diffuse large B cell
lymphoma: An international collaborative study. Blood 2008, in press.

160 Lam LT, Wright G, Davis RE, Lenz G, Farinha P, Dang L, Chan WC,
Rosenwald A, Gascoyne RD, Staudt LM. Cooperative signaling through the
STAT3 and NF-kB pathways in subtypes of diffuse large B cell lymphoma.
Blood 2008 111:3701-13.

166 Lenz G, Wright G, Emre T, Kohlhammer H, Dave SS, Davis RE, Carty S,
Lam L, Shaffer AL, Xiao W, Powell J, Rosenwald A, Muller-Hermelink H-K,
Gascoyne RD, Connors JM, Campo E, Jaffe ES, Delabie J, Smeland EB,
Rimsza LM, Fisher RI, Weisenburger DD, Chan WC, Staudt LM. Gene
expression subtypes of diffuse large B cell lymphoma arise by distinct
genetic pathways. Proc Natl Acad Sci 2008, in press.

167 Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright GW, Dave SS, Zhao
H, Xu W, Rosenwald A, Muller-Hermelink HK, Gascoyne RD, Connors JM,
Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Fisher RI, Chan WC
, Staudt LM. Oncogenic *CARD11* mutations in human diffuse large B cell
lymphoma. Science 2008 319:1676-9.

168 Shaffer AL, Emre NCT, Lamy L, Ngo VN, Xiao W, Wright G, Powell J,
Dave S, Yu X, Zhao H, Zeng Y, Chen B, Epstein J, Staudt LM. IRF4
addiction in multiple myeloma. Nature 2008 454:226-231.